ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology
March 12 2008 - 6:00AM
PR Newswire (US)
SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX
Pharmaceuticals, Inc. (AMEX:ANX) announced today that preliminary
data from the Company's Phase 2 clinical study of ANX-510,
CoFactor(R), for the treatment of advanced breast cancer has been
accepted for presentation at the 2008 American Society of Clinical
Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3,
2008 in Chicago, IL. The poster presentation entitled "5,10
methylenetetrahydrofolic acid with 5-fluorouracil as treatment for
advanced breast cancer in patients who failed prior treatment with
anthracyclines and taxanes: A phase 2 study," is scheduled to be
presented on June 2, 2008. About ANX-510, or CoFactor CoFactor is a
folate-based biomodulator designed to replace leucovorin as the
preferred method to enhance the activity and reduce associated
toxicity of the widely used cancer chemotherapeutic agent 5-FU
(5-fluorouracil). Compared to leucovorin, CoFactor creates more
stable binding between the active form of 5-FU and the target
enzyme, thymidylate synthase. CoFactor bypasses the metabolic
pathway required by leucovorin to deliver the active form of
folate, potentially allowing 5-FU to work more effectively. About
ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals is a
biopharmaceutical company focused on in-licensing, developing and
commercializing proprietary product candidates primarily for the
treatment of cancer and infectious disease. The Company seeks to
improve the performance and commercial potential of existing
treatments by addressing problems associated with these treatment
regimens. More information can be found on ADVENTRX's web site at
http://www.adventrx.com/. Forward Looking Statements ADVENTRX
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they
materialize or do not prove to be accurate, could cause ADVENTRX's
results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: the
potential for ADVENTRX's product candidates to receive regulatory
approval for one or more indications on a timely basis or at all,
and the uncertain process of seeking regulatory approval;
difficulties or delays in developing, testing, manufacturing and
marketing of and obtaining regulatory approval for ADVENTRX's
product candidates; the market potential for ADVENTRX's product
candidates and ADVENTRX's and any future partners' ability to
compete in those markets; unexpected adverse side effects or
inadequate therapeutic efficacy of ADVENTRX's product candidates
that could delay or prevent regulatory approval or
commercialization; the risk that preclinical and clinical results
are not indicative of the success of subsequent clinical trials and
that products will not perform as preclinical and clinical data
suggests or as otherwise anticipated; the risk that ADVENTRX will
be unable to raise sufficient capital to fund the projects
necessary to meet its anticipated or stated goals and milestones;
and other risks and uncertainties more fully described in
ADVENTRX's press releases and periodic filings with the Securities
and Exchange Commission. ADVENTRX's public filings with the
Securities and Exchange Commission are available at
http://www.sec.gov/. You are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date when made. ADVENTRX does not intend to update any
forward-looking statement set forth in this press release to
reflect events or circumstances arising after the date on which it
was made. DATASOURCE: ADVENTRX Pharmaceuticals, Inc. CONTACT:
Investors, Ioana C. Hone of ADVENTRX Pharmaceuticals, Inc.,
+1-858-552-0866 Web site: http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024